JP2022512128A5 - - Google Patents

Info

Publication number
JP2022512128A5
JP2022512128A5 JP2021532111A JP2021532111A JP2022512128A5 JP 2022512128 A5 JP2022512128 A5 JP 2022512128A5 JP 2021532111 A JP2021532111 A JP 2021532111A JP 2021532111 A JP2021532111 A JP 2021532111A JP 2022512128 A5 JP2022512128 A5 JP 2022512128A5
Authority
JP
Japan
Application number
JP2021532111A
Other languages
Japanese (ja)
Other versions
JP2022512128A (ja
JPWO2020115501A5 (https=
Filing date
Publication date
Priority claimed from GBGB1819937.2A external-priority patent/GB201819937D0/en
Priority claimed from GBGB1904339.7A external-priority patent/GB201904339D0/en
Priority claimed from GBGB1911311.7A external-priority patent/GB201911311D0/en
Application filed filed Critical
Priority claimed from PCT/GB2019/053457 external-priority patent/WO2020115501A1/en
Publication of JP2022512128A publication Critical patent/JP2022512128A/ja
Publication of JP2022512128A5 publication Critical patent/JP2022512128A5/ja
Publication of JPWO2020115501A5 publication Critical patent/JPWO2020115501A5/ja
Pending legal-status Critical Current

Links

JP2021532111A 2018-12-06 2019-12-06 医薬化合物およびユビキチン特異的プロテアーゼ19(usp19)阻害剤としてのその使用 Pending JP2022512128A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1819937.2 2018-12-06
GBGB1819937.2A GB201819937D0 (en) 2018-12-06 2018-12-06 Pharmaceutical compounds
GBGB1904339.7A GB201904339D0 (en) 2019-03-28 2019-03-28 Pharmaceutical compounds
GB1904339.7 2019-03-28
GB1911311.7 2019-08-07
GBGB1911311.7A GB201911311D0 (en) 2019-08-07 2019-08-07 Pharmaceutical compounds
PCT/GB2019/053457 WO2020115501A1 (en) 2018-12-06 2019-12-06 Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)

Publications (3)

Publication Number Publication Date
JP2022512128A JP2022512128A (ja) 2022-02-02
JP2022512128A5 true JP2022512128A5 (https=) 2023-01-11
JPWO2020115501A5 JPWO2020115501A5 (https=) 2023-01-11

Family

ID=68887435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021532111A Pending JP2022512128A (ja) 2018-12-06 2019-12-06 医薬化合物およびユビキチン特異的プロテアーゼ19(usp19)阻害剤としてのその使用

Country Status (12)

Country Link
US (1) US20220033397A1 (https=)
EP (1) EP3890829A1 (https=)
JP (1) JP2022512128A (https=)
KR (1) KR20210102285A (https=)
CN (1) CN113365696A (https=)
AU (1) AU2019393162A1 (https=)
BR (1) BR112021010644A2 (https=)
CA (1) CA3121376A1 (https=)
IL (1) IL283706A (https=)
MX (1) MX2021006540A (https=)
SG (1) SG11202105913RA (https=)
WO (1) WO2020115501A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
GB202104097D0 (en) 2021-03-24 2021-05-05 Almac Discovery Ltd Pharmaceutical compounds
GB202311227D0 (en) 2023-07-21 2023-09-06 Almac Discovery Ltd Pharmaceutical compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
ES2309206T3 (es) 2001-10-02 2008-12-16 Smithkline Beecham Corporation Compuestos quimicos.
EP2565186A1 (en) * 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
MA41291A (fr) * 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
AR103297A1 (es) * 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
EP3253765A1 (en) * 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
HK1248220A1 (zh) * 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂
US9938300B2 (en) * 2015-02-05 2018-04-10 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
FR3052452B1 (fr) * 2016-06-10 2018-06-22 Les Laboratoires Servier Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA3027008C (en) * 2016-06-10 2021-02-09 Les Laboratoires Servier (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
GB201612938D0 (en) * 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)